Caixabank holds an indirect stake of 48.1% in BFA via its Portuguese unit Banco BPI, while Angola's state-owned mobile telecoms firm Unitel holds the remaining 51.9%. Earlier this year, Gortazar said ...

In a report released today, Tobey Sommer from Truist Financial assigned a Buy rating to Brink’s Company (BCO – Research Report). The company’s shares closed yesterday at $95.60. According to ...

Money is the key issue in Baku, where negotiators are working on a new amount for aid to help developing nations transition to clean energy, adapt to climate change and deal with weather disasters. It ...

Below is a chart showing RUN's trailing twelve month trading history, with the $18 strike highlighted in orange: Brinks Co (Symbol: BCO) options are showing a volume of 1,193 contracts thus far today.

as it continues to see growth accelerate for the 3rd straight quarter and is winning new big logos (such as Sainsbury's), which lend credence to the value that BCO provides to cash-intensive ...

Banco Santander (ES:SAN) has released an update. Banco Santander has announced that it has repurchased shares worth approximately €688.9 million under its ongoing buyback program, which ...

The 15% stake sold by Rome in Paschi went to Banco BPM SpA, which got 5%, and Anima Holding SpA with 3%, according to statements from the firms. Caltagirone Group bought 3.5% and so did the family of ...

Brink's (BCO) came out with quarterly earnings of $1.51 per share, missing the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.92 per share a year ago. These figures ...

Good morning. Welcome to The Brink’s Company’s Third Quarter 2024 Earnings Call. This morning Brink’s issued a press release detailing its third quarter 2024 results. The company also filed ...

(Reuters) - Colombian financial conglomerate Grupo Aval reported on Wednesday a more than six-fold increase in its third-quarter net profit, climbing to 415.7 billion Colombian pesos ($94.18 million).

In June, GSK released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial of Blenrep in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, ...